These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8773934)

  • 21. Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.
    Madu AA; Mayers M; Perkins R; Liu W; Drusano GL; Aswani R; Madu CN; Miller MH
    Exp Eye Res; 1996 Aug; 63(2):129-36. PubMed ID: 8983970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin.
    Alfaro DV; Davis J; Kim S; Bia F; Bogard JF; Briggs JW; Liggett PE
    Br J Ophthalmol; 1996 Aug; 80(8):755-8. PubMed ID: 8949723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery.
    Yu-Speight AW; Kern TJ; Erb HN
    Vet Ophthalmol; 2005; 8(3):181-7. PubMed ID: 15910371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxacillin for bacterial endophthalmitis: subconjunctival, intravenous, both, or neither?
    Barza M; Kane A; Baum J
    Invest Ophthalmol Vis Sci; 1980 Nov; 19(11):1348-54. PubMed ID: 6968743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by Aspergillus fumigatus.
    Xiang-Gen W; Li-Na Y; Meng X; Hao-Ran J
    J Pharm Sci; 2011 May; 100(5):1745-59. PubMed ID: 21374612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moxalactam (Moxam) in the treatment of experimental staphylococcal endophthalmitis.
    Leeds NH; Peyman GA; House B
    Ophthalmic Surg; 1982 Aug; 13(8):653-6. PubMed ID: 6215601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
    Cheng CK; Berger AS; Pearson PA; Ashton P; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):442-53. PubMed ID: 7843913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):1-7. PubMed ID: 18370872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled release of newer quinolones from biodegradable systems based on poly(lactic acid).
    Andreopoulos AG
    J Biomater Appl; 1995 Oct; 10(2):163-70. PubMed ID: 8618209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intravitreal drug delivery by microspheres of biodegradable polymers].
    Moritera T; Ogura Y; Honda Y; Wada R; Hyon SH; Ikada Y
    Nippon Ganka Gakkai Zasshi; 1990 May; 94(5):508-13. PubMed ID: 2220493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity and pharmacokinetics of intravitreally injected ciprofloxacin in rabbit eyes.
    Rootman DS; Savage P; Hasany SM; Chisholm L; Basu PK
    Can J Ophthalmol; 1992 Oct; 27(6):277-82. PubMed ID: 1451014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular bioerodible minitablets as strategy for the management of microbial keratitis.
    Weyenberg W; Vermeire A; Dhondt MM; Adriaens E; Kestelyn P; Remon JP; Ludwig A
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3229-33. PubMed ID: 15326145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
    Yağci R; Oflu Y; Dinçel A; Kaya E; Yağci S; Bayar B; Duman S; Bozkurt A
    Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies.
    Charoo NA; Kohli K; Ali A
    J Pharm Sci; 2003 Feb; 92(2):407-13. PubMed ID: 12532390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone.
    Sakalar YB; Ozekinci S; Celen MK
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):593-8. PubMed ID: 21834669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of trauma on the ocular penetration of intravenous ciprofloxacin.
    Alfaro DV; Hudson SJ; Rafanan MM; Moss ST; Levy SD
    Am J Ophthalmol; 1996 Nov; 122(5):678-83. PubMed ID: 8909207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity and pharmacokinetics of ciprofloxacin.
    Marchese AL; Slana VS; Holmes EW; Jay WM
    J Ocul Pharmacol; 1993; 9(1):69-76. PubMed ID: 8463734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly[LA-(Glc-Leu)] copolymer as a carrier for ocular delivery of ciprofloxacin: formulation, characterization and in vivo biocompatibility study.
    Pagar KP; Vavia PR
    Ther Deliv; 2013 May; 4(5):553-65. PubMed ID: 23647274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal clearance of moxifloxacin.
    Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER
    Trans Am Ophthalmol Soc; 2005; 103():76-81; discussion 81-3. PubMed ID: 17057790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
    Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.